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Summary
Background Age-related macular degeneration is the most prevalent form of visual impairment and blindness in 
developed countries. Genetic studies have made advancements in establishing the molecular cause of this disease, 
identifying mutations in the complement factor H (CFH) gene and a locus on chromosome 10 encompassing the 
HTRA1/LOC387715/ARMS2 genes. Variants in complement 3 (C3) and an HLA locus containing both factor B 
and C2 genes have also been implicated. We aimed to identify further genetic risk factors for this disease.
Methods We used a case–control study design in a UK sample of patients with age-related macular degeneration 
(n=479) and controls (n=479) and undertook a low-density screen of 32 genes using 93 single nucleotide polymorphisms 
(SNPs). Genes were selected as candidates on the basis of potential functional relevance to age-related macular 
degeneration. Signiﬁ cant initial ﬁ ndings were conﬁ rmed by replication in an independent US cohort of 248 unrelated 
patients with disease and 252 controls, and by high-density genotyping around association signals.
Findings The SNP variant rs2511989, located within intron six of the SERPING1 gene, showed highly signiﬁ cant 
genotypic association with age-related macular degeneration (uncorrected p=4·0×10–⁵, corrected p=0·00372). We 
detected no evidence for association between disease and the other 31 candidate genes. The odds ratio for age-related 
macular degeneration in rs2511989 G/A heterozygotes compared with wild type G/G homozygotes was 0·63 (95% CI 
0·47–0·84). A similar comparison of the A/A homozygotes with the wild type yielded an odds ratio of 0·44 (0·31–0·64). 
We replicated the observed genotypic association in a US cohort (p=0·008). Furthermore, a secondary high-density 
genotyping study across the SERPING1 gene region identiﬁ ed ﬁ ve additional SNP variants similarly associated with 
age-related macular degeneration (rs2244169, rs2511990, rs2509897, rs1005510, and rs2511988). 
Interpretation Genetic variation in SERPING1 signiﬁ cantly alters susceptibility to age-related macular degeneration. 
SERPING1 encodes the C1 inhibitor, which has a crucial role in inhibition of complement component 1 (C1) and 
might implicate the classic pathway of complement activation in this disease.
Funding Macula Vision Research Foundation, the Macular Disease Society, the Wellcome Trust, Brian Mercer Trust, 
the American Health Assistance Foundation, National Institutes of Health, the Howard Hughes Medical Institute.
Introduction
Age-related macular degeneration is the most common 
cause of blindness in developed countries.1,2 In the 
population-based Rotterdam study,3 64% of people aged 
80 years or older showed signs of this disease. The 
prevalence of late or advanced stage age-related macular 
degeneration causing central blindness rises to 11·8% 
after 80 years of age.2 Therefore, because of its high 
prevalence, general practitioners and a wide variety of 
hospital specialists will also have many patients who have 
this disease. As our ageing population expands, the 
economic burden of this disease continues to increase 
every year. In the UK, the yearly economic burden has 
been estimated to be as much as €101·1 million 
(£80·3 million).4 The total yearly costs of health-care 
usage are seven-times higher for patients with age-related 
macular degeneration than for controls. This diﬀ erence 
is largely attributable to a substantial decrease in 
independence and increased need for assistance with 
daily living.5
Clinically, age-related macular degeneration can be 
phenotyped with a grading system, such as that used in 
the Age Related Eye Disease Study (AREDS).6 In this 
classiﬁ cation, the early stages of disease are deﬁ ned on 
the basis of abnormal changes in retinal pigment 
epithelial (RPE) (geographic atrophy, depigmentation, 
and increased pigment), and drusen characteristics (size, 
hard versus soft, distinct or indistinct, and total area). 
However, abnormal changes in advanced stage age-related 
macular degeneration are classiﬁ ed by the presence or 
absence of features such as detachment of RPE, serous 
(or haemorrhagic) sensory retinal detachment, hard 
exudates, subretinal pigment epithelial haemorrhage, 
and subretinal ﬁ brous tissue. In the subset of patients 
who develop neovascular tissue, a rapid loss of central 
vision often occurs within days or weeks as this tissue 
progresses to a ﬁ brovascular scar in the macula. 
If urgent treatment is started with intravitreal injections 
of inhibitors of vascular endothelial growth factor, then 
this process can be stabilised in approximately 90% of 
patients and reversed in approximately 30%.7,8 However, 
these interventions are expensive9,10 and not universally 
available. Therefore, many patients still progress to legal 
blindness when aﬀ ected with this disease.
Lancet 2008; 372: 1828–34
Published Online
October 7, 2008
DOI:10.1016/S0140-
6736(08)61348-3
See Comment page 1788
See Seminar page 1835
Genetic Epidemiology and 
Bioinformatics Group, 
University of Southampton, 
Human Genetics Division 
(Mp 808) (S Ennis PhD, 
Prof A Collins PhD) and Clinical 
Neurosciences Division 
(Mp 806) (C Jomary PhD, 
A Cree BSc, X Chen MSc, 
Prof A Lotery FRCOphth), and 
Southampton Eye Unit 
(A MacLeod FRCOphth, 
Prof A Lotery), Southampton 
General Hospital, 
Southampton, UK; Department 
of Ophthalmology and Visual 
Sciences, University of Iowa, 
Iowa City, IA, USA 
(R Mullins PhD, 
Prof E Stone PhD); The Rayne 
Institute, St Thomas’ Hospital, 
King’s College London, London, 
UK (S Jones PhD); and The 
Howard Hughes Medical 
Institute, Chevy Chase, MD, 
USA (Prof E Stone)
Correspondence to:
Prof Andrew Lotery, Clinical 
Neurosciences Division, 
Mailpoint 806, Southampton 
General Hospital, Southampton 
SO16 6YD, UK
a.j.lotery@southampton.ac.uk
Articles
www.thelancet.com   Vol 372   November 22, 2008 1829
Over recent years, age-related macular degeneration has 
proven an excellent model for the study of complex genetic 
diseases. In 2005, researchers made a major advance-
ment in the understanding of this disease by determining 
that variants in the complement factor H (CFH) gene 
altered susceptibility to age-related macular degene-
ration.11–13 This ﬁ nding added to previous evidence 
suggesting that complement activation contributed to this 
disease.14 Subsequent additional studies implicating other 
genes, some of which are involved in the inﬂ ammatory 
process, have added to understanding the cause of this 
disorder.15–18 However, not all the genes that predispose to 
age-related macular degeneration have been identiﬁ ed.
The serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1 is encoded by the SERPING1 gene (Genbank 
accession NM_000062) and is a member of a large family 
of serine proteases. It was chosen as one of 32 gene 
targets for investigation in this study since the protein 
encoded by this gene (C1 inhibitor) plays a crucial part in 
suppressing the activity of the ﬁ rst component of 
complement (C1). Inhibition of C1 prevents activation of 
complement components 2 and 4 (C2 and C4) and so has 
several downstream eﬀ ects on the complement cascade. 
The C1 inhibitor also inhibits several other serine 
proteinases including plasmin, kallikrein, and coagulation 
factors XIa and XIIa.19 SERPING1 contains eight exons, 
and the product is transcribed from the positive strand of 
chromosome 11q12.1—a region of the genome that has 
not previously been implicated in family studies of 
age-related macular degeneration.20 Mutations in 
SERPING1 that result in either dysfunctional protein or 
subnormal concentrations of protein have been shown to 
cause hereditary angioedema.21,22 We tested SERPING1 
and other candidate genes for their association with age-
related macular degeneration. 
Methods
Study design and patients
We undertook a case–control study between Jan 1, 2008, 
and Aug 20, 2008. The primary UK sample for the 
candidate gene screen consisted of 479 patients with 
age-related macular degeneration (cases) and 
479 un aﬀ ected controls for whom DNA stocks were 
available from an existing cohort. Of the 479 cases with 
disease, 233 were diagnosed as having choroidal ne-
ovascularisation (subretinal neovascular tissue) in at least 
one eye. All participants were white, aged older than 
55 years, and ascertained through the Southampton Eye 
Unit (UK) or research clinics undertaken (by AL) in 
Guernsey (UK). Control patients were either spouses or 
partners of patients with disease or those who presented 
at eye clinics for an unrelated eye disease. An experienced 
retinal specialist examined all participants. Controls 
underwent a dilated retinal examination to exclude any 
clinical signs of age-related macular degeneration. Cases 
and controls were classiﬁ ed as having or not having 
disease on the basis of the AREDS classiﬁ cation system 
(table 1).6 Recruitment was approved by the Southampton 
and Southwest Hants local research ethics committee 
and followed the tenets of the Declaration of Helsinki. 
All participants provided informed written consent and 
underwent a detailed ophthalmic examination to conﬁ rm 
both positive and negative diagnoses.
Procedures 
We obtained a 10 mL peripheral blood sample; DNA was 
extracted according to the salting-out method23 and stored 
at –20°C. 250 ng of each DNA sample was plated out in 
ten 96-well plates and dispatched to the genotyping 
service of the Wellcome Trust Clinical Research Facility 
(WTCRF) in Edinburgh, UK, where samples were 
genotyped using the Illumina GoldenGate assay (Illumina, 
San Diego, CA, USA).24
We selected candidate genes on the basis of putative 
functional relevance, interaction with known genes of 
age-related macular degeneration, or previously impli-
cated biological pathways. Tagging single nucleotide 
polymorphisms (SNPs) with optimal design scores24 on 
the Illumina assay were identiﬁ ed for genotyping.
We used an independent cohort to replicate signiﬁ cant 
ﬁ ndings, which consisted of 248 unrelated patients with 
the clinical diagnosis of age-related macular degeneration 
who were enrolled at the University of Iowa Department 
of Ophthalmology and Visual Sciences, IA, USA, after 
providing written informed consent. All patients had 
been examined by fellowship-trained retina specialists 
and were diagnosed with disease with the same criteria 
as the UK cohort (table 1). We also screened a control 
group of 252 unrelated patients with no history of 
macular degeneration. The patients and controls were 
all enrolled during the same period and by the same 
clinic. All participating US patients with disease and 
controls described themselves as white. We extracted 
DNA from peripheral blood by a previously described 
protocol;25 the SERPING1 rs2511989 SNP was genotyped 
with a TaqMan predesigned SNP genotyping assay 
(Applied Biosystems, Foster City, CA, USA). 
Eyes from human donors were obtained from the 
Iowa Lions Eye Bank (Iowa City, IA, USA) and were 
dissected and frozen within 5 h after death. From this 
UK sample US sample
n Mean age 
(SD [years])
Male:female 
ratio
n Mean age 
(SD [years])
Male:female 
ratio
Controls
0 479 70·59 (9·35) 0·94 252 74·00 (9·04) 0·87
Cases
2 79 71·35 (9·76) 0·72 6 61·17 (8·08) 0·00
3 119 80·61 (8·31) 0·59 48 76·92 (9·50) 0·71
4 281 78·46 (7·87) 0·60 194 82·85 (7·93) 0·67
All cases 479 77·85 (8·83) 0·61 248 81·18 (9·12) 0·65
Table 1: Grade of age-related macular degeneration according to the Age Related Eye Disease Study 
(AREDS) for both UK and US cohorts
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tissue we collected the peripheral neural retina and the 
combined RPE-choroid layers separately. RNA was 
isolated from frozen tissues with the RNeasy kit (Qiagen, 
Valencia, CA, USA), and complementary DNA genera-
tion and PCR were done as described previously.26 We 
used the following primers for PCR analysis—
SERPING1 F1: 5´ -ATT CTC CTA CCC AGC CCA CT-3´ ; 
and SERPING1 R1: 5´ -GGC GTC ACT GTT GTT GCT 
TA-3´ . Primers were designed to amplify a 437 bp 
fragment. We used omission of reverse transcriptase as 
a negative control for these experiments. 
Statistical analyses were done with a combination of 
SPSS (version 14.0) and SAS (version 8.02).
Role of the funding source
The sponsors of the study had no role in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report. SE and AL had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We successfully screened 93 SNPs across 31 genes in the 
UK sample. SNP genotype frequencies were tested in 
controls and conformed to Hardy-Weinberg equilibrium. 
Where multiple SNPs were genotyped across one 
candidate, variants were in very strong linkage dis-
equilibrium (LD). 92 of the 93 tested SNPs showed no 
evidence for association (p>0·01 before correction for 
multiple testing) and were not carried forward for further 
testing. Table 2 provides a list of all genes examined. 
Further information detailing the individual SNPs tested 
is available from the Vision Research group, Clinical 
Neurosciences Division at the University of Southampton. 
However, the rs2511989 SNP within the SERPING1 gene 
exhibited a very strong signal of association (p=5·4×10–⁶), 
which withstood a highly conservative Bonferroni cor-
rection for multiple testing for all 93 SNPs tested 
(p=0·0005). The genotyping call rate at this SNP 
was 99·5%. Table 3 shows the uncorrected and corrected 
p values for allelic and genotypic counts, and the odds 
HUGO gene symbol HUGO gene name Location
1 ITGAM Integrin, alpha M (complement component 3 receptor 3 subunit) 16p11.2
2 C1QTNF1 C1q and tumour necrosis factor related protein 1 17q25
3 CD59 CD59 molecule, complement regulatory protein 11p13
4 MASP1 Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) 3q27-q28
5 MASP2 Mannan-binding lectin serine peptidase 2 1p36.3-p36.2
6 CR2 Complement component (3d/Epstein Barr virus) receptor 2 1q32
7 CR1 Complement component (3b/4b) receptor 1 (Knops blood group) 1q32
8 CRP C-reactive protein, pentraxin-related 1q21-q23
9 VTN Vitronectin 17q11
10 CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 1q32
11 CD46 CD46 molecule, complement regulatory protein 1q32
12 ITGB2 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 21q22.3
13 CLU Clusterin 8p21-p12
14 C4BPA Complement component 4 binding protein, alpha 1q32
15 C4BPB Complement component 4 binding protein, beta 1q32
16 ELN Elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) 7q11.1-q21.1
17 C8A Complement component 8, alpha polypeptide 1p32.2
18 C8B Complement component 8, beta polypeptide 1p36.2-p22.1
19 C9 Complement component 9 5p14-p12
20 C6 Complement component 6 5p13.1
21 C7 Complement component 7 5p13.1
22 SERPING1 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary) 11q12-q13.1
23 APP Amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer’s disease) 21q21.2
24 SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 14q32.1
25 RFX5 Regulatory factor X, 5 (inﬂ uences HLA class II expression) 1q21
26 FGA Fibrinogen alpha chain 4q28
27 FGB Fibrinogen beta chain 4q28
28 FGG Fibrinogen gamma chain 4q28
29 PSEN1 Presenilin 1 (Alzheimer’s disease 3) 14q24.3
30 PSEN2 Presenilin 2 (Alzheimer’s disease 4) 1q31-q42
31 CYP46A1 Cytochrome P450, family 46, subfamily A, polypeptide 1 14q32.1
32 C1QTNF5 C1q and tumour necrosis factor related protein 5 11q23.3
Table 2: Genes tested in primary screen
For the Vision Research group, 
Clinical Neurosciences Division 
see http://www.som.soton.
ac.uk/research/neuro/groups/
vision-research/
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ratios for the A allele, the GA heterozygote, and 
AA homozygote. Two additional SNPs, rs3758919 and 
rs4926, were also genotyped within SERPING1. rs4926 
represents the only HapMap veriﬁ ed non-synonymous 
SNP in this gene, and alters an aminoacid at position 480 
(V480M) in the translated protein. Neither of these 
additionally typed SNPs provided any evidence of 
association with age-related macular degene ration (un-
corrected p=0·94, uncorrected p=0·30, respect ively).
Although samples from Guernsey had an equal 
proportion of cases and controls, and the genotypes from 
Southampton and Guernsey showed no evidence for 
heterogeneity at the rs2511989 SNP (p=0·6), we applied 
genomic control to allow for possible stratiﬁ cation 
because of mixed samples. With use of Devlin and 
Roeder’s method,27 we computed a correction factor 
(λ=1·21) that had no signiﬁ cant eﬀ ect on our ﬁ ndings 
when based on either the uncorrected p value (p=4·5×10–⁶) 
or the corrected p value (p=0·0004) for the number of 
SNPs tested. 
Within both UK and US samples, the control groups 
were signiﬁ cantly younger than were the patients with 
age-related macular degeneration (table 1). This diﬀ erence 
in age might reduce power by potentially diluting the 
control sample with (as yet undeveloped) cases. This 
discrepancy would therefore be expected to make the 
strength of ﬁ ndings more conservative since any 
observed association tests would be underestimated. 
The rs2511989 variant is a non-coding SNP found in 
intron six of SERPING1. The rs2511989 A allele and the 
AA genotype occur less frequently in cases than in con-
trols. This skewed distribution, whereby the (moderately) 
rarer allele occurs signiﬁ cantly more frequently in controls 
than in cases, suggests that it exerts some protective eﬀ ect 
against macular degeneration—thus, the more com-
monly encountered G allele represents the risk allele for 
age-related macular degeneration at this locus. 
In the UK patient samples only, we used the AREDS 
categorisation and applied the Jonckheere-Terpstra test 
for trend to examine for eﬀ ects of carrying zero, one, or 
two alleles at the rs2511989 locus and observed no 
signiﬁ cant trend across the AREDS grades. However, our 
sample size was adequate only to detect quite large 
eﬀ ects, and was not powered to detect more modest but 
nevertheless potentially important eﬀ ects.
To replicate this ﬁ nding, the rs2511989 SNP was 
genotyped in an independent US sample of patients with 
age-related macular degeneration and controls who were 
recruited from the University of Iowa, using the TaqMan 
UK cohort US cohort Combined
Case Control OR (95% CI) Uncorrected 
p value
Corrected 
p value*
Case Control OR (95% CI) p value Case Control OR (95% CI) p value
Allelic 5·4×10–6 0·0005 0·0037 7·49×10–8
G 597 (63%) 500 (52%) .. .. .. 322 (65%) 282 (56%) .. .. 919 (64%) 782 (54%) .. ..
A 355 (37%) 454 (48%) 0·65 
(0·55–0·79)†
.. .. 174 (35%) 222 (44%) 0·69 
(0·53–0·89)†
.. 529 (37%) 676 (46%) 0·67 
(0·57–0·77)†
..
Genotypic 4·0×10–5 0·0037 0·0080 6·08×10–7
GG 191 (40%) 132 (28%) .. .. .. 100 (40%) 79 (31%) .. .. 291 (40%) 211 (29%) ..
GA 215 (45%) 236 (50%) 0·63 
(0·47–0·84)‡
.. .. 122 (49%) 124 (49%) 0·77 
(0·53–1·14)‡
.. 337 (47%) 360 (49%) 0·68 
(0·54–0·86)‡
..
AA 70 (15%) 109 (23%) 0·44 
(0·31–0·64)‡
.. .. 26 (11%) 49 (19%) 0·42 
(0·24–0·73)‡
.. 96 (13%) 158 (22%) 0·44 
(0·32–0·60)‡
..
*Corrected for 93 single nucleotide polymorphisms. †Relative to G allele. ‡Relative to wildtype (GG) homozyte. 
Table 3: Allelic and genotypic tests of rs2511989 from primary screen of UK sample (n=953), US sample (n=500), and the two cohorts combined
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Figure 1: Association across SERPING1 region with age-related macular degeneration
The x-axis shows the relative positions of the 11 single nucleotide polymorphisms (SNPs) genotyped in the UK 
sample using the University of California Santa Cruz, March, 2006, reference sequence (NCBI build 36.1). 
The green diamond represents rs2511989, which was genotyped in both the original scan and the follow-up scan. 
The blue squares depict SNPs genotyped in the initial candidate gene scan. The red dots depict the SNPs that were 
typed in the follow-up scan only. The probability threshold for signiﬁ cance Bonferroni corrected for the 93 SNPs 
genotyped in the initial scan plus the eight additional SNPs genotyped in the follow-up is represented by a dashed 
green line. The y-axis shows the negative natural log of the p value for association using the Cochrane-Armitage 
test. The SERPING1 gene is drawn to scale and shows all eight exons. Exon one is untranslated (red bars), whereas 
exons two and eight are partially translated. Exons three to seven are translated (blue bars). 
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method. We observed a very similar proﬁ le of allelic and 
genotypic counts at the rs2511989 SNP within this distinct 
sample (table 3). The level of signiﬁ cance was strongest 
in the UK sample for the allelic comparison (table 3). 
However, despite smaller numbers in the US sample, 
results were very similar to those for the UK sample after 
correction. The observed odds ratios for the AA genotype 
were very similar between studies, with a slightly 
narrower conﬁ dence interval in the UK samples than in 
the US samples due to greater sample size (table 3). 
We observed no evidence of heterogeneity in the 
distribution of rs2511989 genotypes between the UK and 
US samples, with both showing the same trend of an 
excess of the rarer AA genotype within the control group 
(table 3). Combining genotype counts from the two 
samples yielded a p value for genotypic association of 
6·08×10–⁷ for this variant with age-related macular 
degeneration (table 3).
Our modest preliminary scan of the SERPING1 gene 
produced one highly associated SNP (rs2511989) and 
two non-associated SNPs (rs3758919 and rs4926). 
Although observation of non-associated SNPs within the 
imme diate genomic vicinity of strongly associated SNPs 
is not unusual,11 we would expect that other variants 
within the region should provide supporting evidence for 
the association. Therefore, we undertook a secondary 
scan of SERPING1 with all common (minor allele fre-
quency >0·05) tagging SNP variants across the 15 kilobase 
(kb) gene (n=3) and additional SNP variants both 5´  
and 3´  of the gene (n=5). All additional SNPs were 
non-coding and had no reported functional relevance. 
DNA from the UK sample (n=958) was dispatched to 
KBioscience for genotyping with KASPar chemistry as 
previously described. For quality control purposes, we 
included the rs2511989 SNP to be re-genotyped alongside 
eight additional SNPs.
At the rs2511989 SNP, 26 samples were not assigned 
genotype calls with the KBioscience platform, which 
compares to ﬁ ve such no calls with the Illumina platform 
in the initial analysis. No sample failed on both platforms. 
The 927 samples successfully genotyped at the rs2511989 
SNP on both platforms showed 99·9% concordance. All 
SNPs conformed to Hardy Weinberg equilibrium as 
tested in the control sample. We used the 
Cochran-Armitage test for trend28 to examine association 
and plotted the negative natural log of the resultant 
p values (ﬁ gure 1). Of the eight new SNPs genotyped in 
this secondary scan of the gene (red dots), ﬁ ve showed 
very strong signiﬁ cance, supporting the ﬁ ndings for 
rs2511989, and withstood a conservative Bonferroni 
correction for multiple testing of 93 SNPs in the original 
scan plus eight additional SNPs in the secondary 
SERPING1 scan (dashed green line). One SNP, rs2509897, 
which lies 2·5 kb 5´  of the transcriptional start site of the 
SERPING1 gene and adjacent to a predicted promoter 
region, exhibited the strongest signal for association 
(p=6·17×10–⁶). The region en com passing all 11 SNPs 
showed very strong LD with pair wise D´ =1 between the 
leftmost rs2649663 and rightmost rs10896632 SNPs in 
the HapMap Ceu data. 
We assessed the association between SERPING1 and 
age-related macular degeneration in the presence of 
other genetic and environmental factors. We used step-
wise logistic regression analysis of disease aﬀ ection 
status against our most associated SNP genotypes from 
the CFH gene, Chr10q locus, and SERPING1 (rs1061170, 
rs11200638, and rs2509897, respectively) and controlled 
for age, sex, and smoking status. The rs2509897 SNP 
entered the model and was signiﬁ cant for association in 
the presence of these confounding factors (p=0·001).
In RT-PCR experiments, ampliﬁ cation of a PCR product 
of the appropriate molecular weight was obtained from 
complementary DNA from both neural retina and 
RPE-choroid (ﬁ gure 2). This ﬁ nding is consistent with 
expression microarray data from the same tissues 
(R Mullins, unpublished data) and indicates that cells in 
the neural retina and RPE or choroid, or both, synthesise 
SERPING1 mRNA locally.
Discussion
Of the 32 genes that we screened for association with 
age-related macular degeneration in a UK cohort, 
RET
+rt –rt +rt –rt
RPE/CH
Figure 2: Expression analysis with RT-PCR showing ampliﬁ cation of 
complementary DNA for SERPING1 in both neural retina (RET) and 
RPE-choroidal tissues (RPE/CH) 
No product was ampliﬁ ed from either tissue when the reverse transcription step 
was omitted (–rt).
For the KASPar chemistry see 
http://www.kbioscience.co.uk/
genotyping/genotyping_
chemistry.html. 
For the international HapMap 
project see http://www.hapmap.
org/
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31 showed no evidence of association with this disease. 
However, we identiﬁ ed a strong association signal 
between a genetic variant in SERPING1 and age-related 
macular degeneration, and replicated this ﬁ nding in an 
independent sample. Our results indicate that the slightly 
rarer rs2511989 AA genotype is present signiﬁ cantly 
more frequently in controls than in cases and provides a 
protective eﬀ ect against development of age-related 
macular degeneration.
We also genotyped a non-coding SNP situated about 
2 kb 5´  of SERPING1 (rs3758919) and a non-synonymous 
SNP at the 3´  end of the gene (rs4926) in SERPING1 as 
part of the preliminary candidate gene scan, but we 
observed no association with age-related macular 
degeneration. Therefore, a secondary higher density 
genotyping experiment was undertaken across the 
SERPING1 gene region. This secondary scan revealed 
ﬁ ve additional SNPs from across the region that also 
showed very strong association with the disease. The 
most signiﬁ cantly associated SNP, rs2509897, lies in the 
promoter region of the gene. However, in view of the very 
strong LD evident across SERPING1, further detailed 
functional studies are needed to identify which other 
genetic variants (SNPs, microsatellites, insertions, dele-
tions) lie in close genetic proximity to our markers and to 
assess their possible contribution to expression and 
function. As with many other genes, multiple variants 
across this locus might aﬀ ect disease status or severity.
RT-PCR of SERPING1 mRNA (ﬁ gure 2) shows 
expression of SERPING1 mRNA in both retina and RPE-
choroid layers of eyes from human donors. The 
expression of SERPING1 in the tissues predominantly 
aﬀ ected by age-related macular degeneration adds to the 
evidence that this protein might have a regulatory role 
for the complement system in ocular physiology. 
The complement system is a powerful component of 
innate immunity which recognises and facilitates the 
elimination of pathogens and unwanted host material.29 
Variants within several genes that code for proteins 
involved in the complement cascade are recognised to 
either signiﬁ cantly increase the risk of age-related 
macular degeneration (CFH11–13 and complement C318) or 
decrease this risk (C2 and factor B16 and deletion of CFH 
related genes CFHR1 and CFHR330). 
The protein product of SERPING1 regulates the ﬁ rst 
component of complement (C1) by inhibition of the 
proteolytic activity of its subcomponents C1r and C1s.19 It 
is a member of a large serine protease inhibitor (serpin) 
gene family and also inhibits several other serine 
proteinases, including plasmin, kallikrein, and coagulation 
factors XIa and XIIa.19 Mutation in SERPING1 causes 
hereditary angioedema.21 Inhibition of the proteolytic 
subcomponents of C1 via genetic variation in SERPING1 
might implicate the classic pathway of complement 
activation in age-related macular degeneration. 
In summary, our study shows a strong association 
between age-related macular degeneration and SERPING1, 
with supporting evidence from an independent replication 
and a secondary high-density scan of the gene. Further 
studies are now required to assess this association in 
independent populations of various ethnic origins. 
Furthermore, functional studies that are capable of 
discriminating between variants that cause disease and 
those which are co-inherited with a causal mutation, are 
now needed. Our ﬁ ndings add to the growing under-
standing of the genetics of age-related macular 
degeneration, which should ultimately lead to novel treat-
ments for this common and devastating disease. 
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